Review Article
No access
Published Online: 25 September 2015

TrxR1 as a Potent Regulator of the Nrf2-Keap1 Response System

Publication: Antioxidants & Redox Signaling
Volume 23, Issue Number 10

Abstract

Significance: All cells must maintain a balance between oxidants and reductants, while allowing for fluctuations in redox states triggered by signaling, altered metabolic flow, or extracellular stimuli. Furthermore, they must be able to rapidly sense and react to various challenges that would disrupt the redox homeostasis. Recent Advances: Many studies have identified Keap1 as a key sensor for oxidative or electrophilic stress, with modification of Keap1 by oxidation or electrophiles triggering Nrf2-mediated transcriptional induction of enzymes supporting reductive and detoxification pathways. However, additional mechanisms for Nrf2 regulation are likely to exist upstream of, or in parallel with, Keap1. Critical Issues: Here, we propose that the mammalian selenoprotein thioredoxin reductase 1 (TrxR1) is a potent regulator of Nrf2. A high chemical reactivity of TrxR1 and its vital role for the thioredoxin (Trx) system distinguishes TrxR1 as a prime target for electrophilic challenges. Chemical modification of the selenocysteine (Sec) in TrxR1 by electrophiles leads to rapid inhibition of thioredoxin disulfide reductase activity, often combined with induction of NADPH oxidase activity of the derivatized enzyme, thereby affecting many downstream redox pathways. The notion of TrxR1 as a regulator of Nrf2 is supported by many publications on effects in human cells of selenium deficiency, oxidative stress or electrophile exposure, as well as the phenotypes of genetic mouse models. Future Directions: Investigation of the role of TrxR1 as a regulator of Nrf2 activation will facilitate further studies of redox control in diverse cells and tissues of mammals, and possibly also in animals of other classes. Antioxid. Redox Signal. 23, 823–853.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Abel EL, Bubel JD, Simper MS, Powell L, McClellan SA, Andreeff M, MacLeod MC, and DiGiovanni J. Protection against 2-chloroethyl ethyl sulfide (CEES)-induced cytotoxicity in human keratinocytes by an inducer of the glutathione detoxification pathway. Toxicol Appl Pharmacol 255: 176–183, 2011.
2.
Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, and Klaassen CD. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 335: 2–12, 2010.
3.
Alloul-Ramdhani M, Tensen CP, and El Ghalbzouri A. Performance of the N/TERT epidermal model for skin sensitizer identification via Nrf2-Keap1-ARE pathway activation. Toxicol In Vitro 28: 982–989, 2014.
4.
Anestal K and Arner ES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278: 15966–15972, 2003.
5.
Anestal K, Prast-Nielsen S, Cenas N, and Arner ES. Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS One 3: e1846, 2008.
6.
Anestål K and Arnér ESJ. Rapid Induction of Cell Death by Selenium-compromised Thioredoxin Reductase 1 but Not by the Fully Active Enzyme Containing Selenocysteine. J Biol Chem 278: 15966–15972, 2003.
7.
Aono J, Yanagawa T, Itoh K, Li B, Yoshida H, Kumagai Y, Yamamoto M, and Ishii T. Activation of Nrf2 and accumulation of ubiquitinated A170 by arsenic in osteoblasts. Biochem Biophys Res Commun 305: 271–277, 2003.
8.
Arai RJ, Masutani H, Yodoi J, Debbas V, Laurindo FR, Stern A, and Monteiro HP. Nitric oxide induces thioredoxin-1 nuclear translocation: possible association with the p21Ras survival pathway. Biochem Biophys Res Commun 348: 1254–1260, 2006.
9.
Arbiser JL, Klauber N, Rohan R, van Leeuwen R, Huang MT, Fisher C, Flynn E, and Byers HR. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4: 376–383, 1998.
10.
Arner ES. Superoxide production by dinitrophenyl-derivatized thioredoxin reductase—a model for the mechanism and correlation to immunostimulation by dinitrohalobenzenes. Biofactors 10: 219–226, 1999.
11.
Arner ES. Focus on mammalian thioredoxin reductases—important selenoproteins with versatile functions. Biochim Biophys Acta 1790: 495–526, 2009.
12.
Arner ES, Bjornstedt M, and Holmgren A. 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J Biol Chem 270: 3479–3482, 1995.
13.
Arner ES and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102–6109, 2000.
14.
Arner ES and Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 16: 420–426, 2006.
15.
Arner ES, Nakamura H, Sasada T, Yodoi J, Holmgren A, and Spyrou G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 31: 1170–1178, 2001.
16.
Arnér ESJ. Focus on mammalian thioredoxin reductases–important selenoproteins with versatile functions. Biochim Biophys Acta 1790: 495–526, 2009.
17.
Arnér ESJ. Selenoproteins-What unique properties can arise with selenocysteine in place of cysteine? Exp Cell Res 316: 1296–1303, 2010.
18.
Arnér ESJ, Björnstedt M, and Holmgren A. 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase: loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity. J Biol Chem 270: 3479–3482, 1995.
19.
Arnér ESJ, Sarioglu H, Lottspeich F, Holmgren A, and Böck A. High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J Mol Biol 292: 1003–1016, 1999.
20.
Arredondo F, Echeverry C, Abin-Carriquiry JA, Blasina F, Antunez K, Jones DP, Go YM, Liang YL, and Dajas F. After cellular internalization, quercetin causes Nrf2 nuclear translocation, increases glutathione levels, and prevents neuronal death against an oxidative insult. Free Radic Biol Med 49: 738–747, 2010.
21.
Ashino T, Sugiuchi J, Uehara J, Naito-Yamamoto Y, Kenmotsu S, Iwakura Y, Shioda S, Numazawa S, and Yoshida T. Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1. J Toxicol Sci 36: 635–643, 2011.
22.
Baird L and Dinkova-Kostova AT. Diffusion dynamics of the Keap1-Cullin3 interaction in single live cells. Biochem Biophys Res Commun 433: 58–65, 2013.
23.
Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, and Motterlini R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371: 887–895, 2003.
24.
Banerjee R. Redox Metabolism and Life. In: Redox Biochemistry, edited by Banerjee R, Becker DF, Dickman MB, Gladyshev VN, and Ragsdale SW. Hoboken, NJ: John Wiley & Sons, Inc., 2008.
25.
Banning A, Deubel S, Kluth D, Zhou Z, and Brigelius-Flohe R. The GI-GPx gene is a target for Nrf2. Mol Cell Biol 25: 4914–4923, 2005.
26.
Becker K, Gromer S, Schirmer RH, and Müller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 267: 6118–6125, 2000.
27.
Benhar M, Forrester MT, Hess DT, and Stamler JS. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science 320: 1050–1054, 2008.
28.
Biterova EI, Turanov AA, Gladyshev VN, and Barycki JJ. Crystal structures of oxidized and reduced mitochondrial thioredoxin reductase provide molecular details of the reaction mechanism. Proc Natl Acad Sci U S A 102: 15018–15023, 2005.
29.
Black AT, Joseph LB, Casillas RP, Heck DE, Gerecke DR, Sinko PJ, Laskin DL, and Laskin JD. Role of MAP kinases in regulating expression of antioxidants and inflammatory mediators in mouse keratinocytes following exposure to the half mustard, 2-chloroethyl ethyl sulfide. Toxicol Appl Pharmacol 245: 352–360, 2010.
30.
Bloom D, Dhakshinamoorthy S, and Jaiswal AK. Site-directed mutagenesis of cysteine to serine in the DNA binding region of Nrf2 decreases its capacity to upregulate antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene 21: 2191–2200, 2002.
31.
Branco V, Godinho-Santos A, Goncalves J, Lu J, Holmgren A, and Carvalho C. Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds. Free Radic Biol Med 73: 95–105, 2014.
32.
Brigelius-Flohe R and Flohe L. Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal 15: 2335–2381, 2011.
33.
Brigelius-Flohe R and Maiorino M. Glutathione peroxidases. Biochim Biophys Acta 1830: 3289–3303, 2013.
34.
Brigelius-Flohe R, Muller M, Lippmann D, and Kipp AP. The yin and yang of nrf2-regulated selenoproteins in carcinogenesis. Int J Cell Biol 2012: 486147, 2012.
35.
Brown KK, Eriksson SE, Arner ES, and Hampton MB. Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. Free Radic Biol Med 45: 494–502, 2008.
36.
Burk RF, Hill KE, Nakayama A, Mostert V, Levander XA, Motley AK, Johnson DA, Johnson JA, Freeman ML, and Austin LM. Selenium deficiency activates mouse liver Nrf2-ARE but vitamin E deficiency does not. Free Radic Biol Med 44: 1617–1623, 2008.
37.
Cabello CM, Bair WB 3rd, Lamore SD, Ley S, Bause AS, Azimian S, and Wondrak GT. The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radic Biol Med 46: 220–231, 2009.
38.
Cai W, Zhang B, Duan D, Wu J, and Fang J. Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells. Toxicol Appl Pharmacol 262: 341–348, 2012.
39.
Cai W, Zhang L, Song Y, Wang B, Zhang B, Cui X, Hu G, Liu Y, Wu J, and Fang J. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic Biol Med 52: 257–265, 2012.
40.
Calabrese V, Cornelius C, Maiolino L, Luca M, Chiaramonte R, Toscano MA, and Serra A. Oxidative stress, redox homeostasis and cellular stress response in Meniere's disease: role of vitagenes. Neurochem Res 35: 2208–2217, 2010.
41.
Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, and Butterfield DA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8: 1975–1986, 2006.
42.
Carlson BA, Moustafa ME, Sengupta A, Schweizer U, Shrimali R, Rao M, Zhong N, Wang S, Feigenbaum L, Lee BJ, Gladyshev VN, and Hatfield DL. Selective restoration of the selenoprotein population in a mouse hepatocyte selenoproteinless background with different mutant selenocysteine tRNAs lacking Um34. J Biol Chem 282: 32591–32602, 2007.
43.
Carlson BA, Novoselov SV, Kumaraswamy E, Lee BJ, Anver MR, Gladyshev VN, and Hatfield DL. Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J Biol Chem 279: 8011–8017, 2004.
44.
Carlson BA, Yoo MH, Tobe R, Mueller C, Naranjo-Suarez S, Hoffmann VJ, Gladyshev VN, and Hatfield DL. Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis. Carcinogenesis 33: 1806–1813, 2012.
45.
Carvalho CM, Chew EH, Hashemy SI, Lu J, and Holmgren A. Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity. J Biol Chem 283: 11913–11923, 2008.
46.
Cassidy PB, Edes K, Nelson CC, Parsawar K, Fitzpatrick FA, and Moos PJ. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 27: 2538–2549, 2006.
47.
Castellano S. On the unique function of selenocysteine—Insights from the evolution of selenoproteins. Biochim Biophys Acta 1790: 1463–1470, 2009.
48.
Castellano S, Andres AM, Bosch E, Bayes M, Guigo R, and Clark AG. Low exchangeability of selenocysteine, the 21st amino acid, in vertebrate proteins. Mol Biol Evol 26: 2031–2040, 2009.
49.
Cenas N, Nivinskas H, Anusevicius Z, Sarlauskas J, Lederer F, and Arner ES. Interactions of quinones with thioredoxin reductase: a challenge to the antioxidant role of the mammalian selenoprotein. J Biol Chem 279: 2583–2592, 2004.
50.
Cenas N, Prast S, Nivinskas H, Sarlauskas J, and Arner ES. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J Biol Chem 281: 5593–5603, 2006.
51.
Chang CF, Cho S, and Wang J. (-)-Epicatechin protects hemorrhagic brain via synergistic Nrf2 pathways. Ann Clin Transl Neurol 1: 258–271, 2014.
52.
Chang M, Burgess JR, Scholz RW, and Reddy CC. The induction of specific rat liver glutathione S-transferase subunits under inadequate selenium nutrition causes an increase in prostaglandin F2 alpha formation. J Biol Chem 265: 5418–5423, 1990.
53.
Chartoumpekis D, Ziros PG, Psyrogiannis A, Kyriazopoulou V, Papavassiliou AG, and Habeos IG. Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway. Biochem Biophys Res Commun 396: 463–466, 2010.
54.
Chen C, Yu R, Owuor ED, and Kong AN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 23: 605–612, 2000.
55.
Chen ZH, Saito Y, Yoshida Y, Sekine A, Noguchi N, and Niki E. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J Biol Chem 280: 41921–41927, 2005.
56.
Cheng Q, Sandalova T, Lindqvist Y, and Arnér ESJ. Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 284: 3998–4008, 2009.
57.
Cheng YT, Wu CH, Ho CY, and Yen GC. Catechin protects against ketoprofen-induced oxidative damage of the gastric mucosa by up-regulating Nrf2 in vitro and in vivo. J Nutr Biochem 24: 475–483, 2013.
58.
Chew EH, Nagle AA, Zhang Y, Scarmagnani S, Palaniappan P, Bradshaw TD, Holmgren A, and Westwell AD. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radic Biol Med 48: 98–111, 2010.
59.
Chia AJ, Goldring CE, Kitteringham NR, Wong SQ, Morgan P, and Park BK. Differential effect of covalent protein modification and glutathione depletion on the transcriptional response of Nrf2 and NF-kappaB. Biochem Pharmacol 80: 410–421, 2010.
60.
Choi SY, Son TG, Park HR, Jang YJ, Oh SB, Jin B, and Lee J. Naphthazarin has a protective effect on the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson's disease model. J Neurosci Res 90: 1842–1849, 2012.
61.
Christensen MJ, Nelson BL, and Wray CD. Regulation of glutathione S-transferase gene expression and activity by dietary selenium. Biochem Biophys Res Commun 202: 271–277, 1994.
62.
Copple IM, Goldring CE, Jenkins RE, Chia AJ, Randle LE, Hayes JD, Kitteringham NR, and Park BK. The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology 48: 1292–1301, 2008.
63.
Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, and Visvanathan K. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis 28: 1485–1490, 2007.
64.
Covas G, Marinho HS, Cyrne L, and Antunes F. Activation of Nrf2 by H2O2: de novo synthesis versus nuclear translocation. Methods Enzymol 528: 157–171, 2013.
65.
Dagnell M, Frijhoff J, Pader I, Augsten M, Boivin B, Xu J, Mandal PK, Tonks NK, Hellberg C, Conrad M, Arner ES, and Ostman A. Selective activation of oxidized PTP1B by the thioredoxin system modulates PDGF-beta receptor tyrosine kinase signaling. Proc Natl Acad Sci U S A 110: 13398–13403, 2013.
66.
Dal Piaz F, Braca A, Belisario MA, and De Tommasi N. Thioredoxin system modulation by plant and fungal secondary metabolites. Curr Med Chem 17: 479–494, 2010.
67.
Dammeyer P, Hellberg V, Wallin I, Laurell G, Shoshan M, Ehrsson H, Arner ES, and Kirkegaard M. Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures. Acta Otolaryngol 134: 448–454, 2014.
68.
de Castro E, Hegi de Castro S, and Johnson TE. Isolation of long-lived mutants in Caenorhabditis elegans using selection for resistance to juglone. Free Radic Biol Med 37: 139–145, 2004.
69.
Delaunay A, Pflieger D, Barrault MB, Vinh J, and Toledano MB. A thiol peroxidase is an H2O2 receptor and redox-transducer in gene activation. Cell 111: 471–481, 2002.
70.
Ding Y, Zhang B, Zhou K, Chen M, Wang M, Jia Y, Song Y, Li Y, and Wen A. Dietary ellagic acid improves oxidant-induced endothelial dysfunction and atherosclerosis: role of Nrf2 activation. Int J Cardiol 175: 508–514, 2014.
71.
Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, and Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 99: 11908–11913, 2002.
72.
Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, and Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci U S A 98: 3404–3409, 2001.
73.
Dinkova-Kostova AT, and Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 20: 911–914, 1999.
74.
Dodmane PR, Arnold LL, Kakiuchi-Kiyota S, Qiu F, Liu X, Rennard SI, and Cohen SM. Cytotoxicity and gene expression changes induced by inorganic and organic trivalent arsenicals in human cells. Toxicology 312: 18–29, 2013.
75.
Du Y, Zhang H, Lu J, and Holmgren A. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose. J Biol Chem 287: 38210–38219, 2012.
76.
Du Y, Zhang H, Zhang X, Lu J, and Holmgren A. Thioredoxin 1 is inactivated due to oxidation induced by peroxiredoxin under oxidative stress and reactivated by the glutaredoxin system. J Biol Chem 288: 32241–32247, 2013.
77.
Duan D, Zhang B, Yao J, Liu Y, and Fang J. Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells. Free Radic Biol Med 70: 182–193, 2014.
78.
Eckenroth BE, Lacey BM, Lothrop AP, Harris KM, and Hondal RJ. Investigation of the C-terminal redox center of high-Mr thioredoxin reductase by protein engineering and semisynthesis. Biochemistry 46: 9472–9483, 2007.
79.
Eckenroth BE, Rould MA, Hondal RJ, and Everse SJ. Structural and biochemical studies reveal differences in the catalytic mechanisms of mammalian and Drosophila melanogaster thioredoxin reductases. Biochemistry 46: 4694–4705, 2007.
80.
Ekstrom L, Johansson M, Monostory K, Rundlof AK, Arner ES, and Bjorkhem-Bergman L. Simvastatin inhibits the core promoter of the TXNRD1 gene and lowers cellular TrxR activity in HepG2 cells. Biochem Biophys Res Commun 430: 90–94, 2013.
81.
El-Sayed WM, Aboul-Fadl T, Lamb JG, Roberts JC, and Franklin MR. Effect of selenium-containing compounds on hepatic chemoprotective enzymes in mice. Toxicology 220: 179–188, 2006.
82.
Engelman R, Weisman-Shomer P, Ziv T, Xu J, Arner ES, and Benhar M. Multilevel regulation of 2-Cys peroxiredoxin reaction cycle by S-nitrosylation. J Biol Chem 288: 11312–11324, 2013.
83.
Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, and Arner ES. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. Free Radic Biol Med 47: 1661–1671, 2009.
84.
Ernst IM, Wagner AE, Schuemann C, Storm N, Hoppner W, Doring F, Stocker A, and Rimbach G. Allyl-, butyl- and phenylethyl-isothiocyanate activate Nrf2 in cultured fibroblasts. Pharmacol Res 63: 233–240, 2011.
85.
Espinosa-Diez C, Fierro-Fernandez M, Sanchez-Gomez FJ, Rodriguez-Pascual F, Alique M, Ruiz-Ortega M, Beraza N, Martinez-Chantar ML, Fernandez-Hernando C, and Lamas S. Targeting of gamma-glutamyl-cysteine ligase by miR-433 reduces glutathione biosynthesis and promotes TGF-beta-dependent fibrogenesis. Antioxid Redox Signal, 2015 [Epub ahead of print];.
86.
Evans JP, Xu F, Sirisawad M, Miller R, Naumovski L, and de Montellano PR. Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities. Mol Pharmacol 71: 193–200, 2007.
87.
Fahey JW and Kensler TW. Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes. Chem Res Toxicol 20: 572–576, 2007.
88.
Fang J and Holmgren A. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J Am Chem Soc 128: 1879–1885, 2006.
89.
Fang J, Lu J, and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280: 25284–25290, 2005.
90.
Fernandes AP and Holmgren A. Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid Redox Signal 6: 63–74, 2004.
91.
Flohé L. Changing paradigms in thiology: from antioxidant defense toward redox regulation. Methods Enzymol 473: 1–39, 2010.
92.
Fourquet S, Guerois R, Biard D, and Toledano MB. Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J Biol Chem 285: 8463–8471, 2010.
93.
Freemerman AJ, Gallegos A, and Powis G. Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res 59: 4090–4094, 1999.
94.
Fritz-Wolf K, Kehr S, Stumpf M, Rahlfs S, and Becker K. Crystal structure of the human thioredoxin reductase-thioredoxin complex. Nat Commun 2: 383, 2011.
95.
Fritz-Wolf K, Urig S, and Becker K. The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis. J Mol Biol 370: 116–127, 2007.
96.
Funato Y and Miki H. Reversible oxidation of PRL family protein-tyrosine phosphatases. Methods 65: 184–189, 2014.
97.
Garg R, Gupta S, and Maru GB. Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action. Carcinogenesis 29: 1022–1032, 2008.
98.
Gladyshev VN, Jeang K-T, and Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci (USA) 93: 6146–6151, 1996.
99.
Go YM and Jones DP. Redox control systems in the nucleus: mechanisms and functions. Antioxid Redox Signal 13: 489–509, 2010.
100.
Gorlatov SN and Stadtman TC. Human thioredoxin reductase from HeLa cells: selective alkylation of selenocysteine in the protein inhibits enzyme activity and reduction with NADPH influences affinity to heparin. Proc Natl Acad Sci USA 95: 8520–8525, 1998.
101.
Granado-Serrano AB, Martin MA, Bravo L, Goya L, and Ramos S. Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: involvement of p38. Chem Biol Interact 195: 154–164, 2012.
102.
Grek CL, Zhang J, Manevich Y, Townsend DM, and Tew KD. Causes and consequences of cysteine S-glutathionylation. J Biol Chem 288: 26497–26504, 2013.
103.
Grippo JF, Holmgren A, and Pratt WB. Proof that the endogenous, heat-stable glucocorticoid receptor-activating factor is thioredoxin. J Biol Chem 260: 93–97, 1985.
104.
Gromer S, Arscott LD, Williams CH Jr., Schirmer RH, and Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273: 20096–20101, 1998.
105.
Gromer S, Johansson L, Bauer H, Arscott LD, Rauch S, Ballou DP, Williams CH Jr., Schirmer RH, and Arner ES. Active sites of thioredoxin reductases: why selenoproteins? Proc Natl Acad Sci U S A 100: 12618–12623, 2003.
106.
Gromer S, Merkle H, Schirmer RH, and Becker K. Human placenta thioredoxin reductase: preparation and inhibitor studies. Methods Enzymol 347: 382–394, 2002.
107.
Gromer S, Schirmer RH, and Becker K. The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase. FEBS Lett 412: 318–320, 1997.
108.
Gromer S, Urig S, and Becker K. The thioredoxin system—from science to clinic. Med Res Rev 24: 40–89, 2004.
109.
Gu L, Deng WS, Liu Y, Jiang CH, Sun LC, Sun XF, Xu Q, and Zhou H. Ellagic acid protects Lipopolysaccharide/d-galactosamine-induced acute hepatic injury in mice. Int Immunopharmacol 22: 341–345, 2014.
110.
Halliwell B and Gutteridge J. Free Radicals in Biology and Medicine. New York: Oxford University Press, 2007.
111.
Hanneken A, Lin FF, Johnson J, and Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci 47: 3164–3177, 2006.
112.
Hansen JM, Watson WH, and Jones DP. Compartmentation of Nrf-2 redox control: regulation of cytoplasmic activation by glutathione and DNA binding by thioredoxin-1. Toxicol Sci 82: 308–317, 2004.
113.
Harris IS, Blaser H, Moreno J, Treloar AE, Gorrini C, Sasaki M, Mason JM, Knobbe CB, Rufini A, Halle M, Elia AJ, Wakeham A, Tremblay ML, Melino G, Done S, and Mak TW. PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling. Oncogene 33: 1047–1054, 2014.
114.
Hashemy SI and Holmgren A. Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. J Biol Chem 283: 21890–21898, 2008.
115.
Hashemy SI, Ungerstedt JS, Zahedi Avval F, and Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281: 10691–10697, 2006.
116.
Hayes JD, Flanagan JU, and Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51–88, 2005.
117.
He X, Chen MG, Lin GX, and Ma Q. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2×Keap1×Cul3 complex and recruiting Nrf2×Maf to the antioxidant response element enhancer. J Biol Chem 281: 23620–23631, 2006.
118.
He X and Ma Q. Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol Exp Ther 332: 66–75, 2010.
119.
Heidler T, Hartwig K, Daniel H, and Wenzel U. Caenorhabditis elegans lifespan extension caused by treatment with an orally active ROS-generator is dependent on DAF-16 and SIR-2.1. Biogerontology 11: 183–195, 2010.
120.
Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, Eksborg S, Arner ES, Shoshan M, Ehrsson H, and Laurell G. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 101: 37–47, 2009.
121.
Herrmann JM and Dick TP. Redox Biology on the rise. Biol Chem 393: 999–1004, 2012.
122.
Higgins LG and Hayes JD. The cap'n'collar transcription factor Nrf2 mediates both intrinsic resistance to environmental stressors and an adaptive response elicited by chemopreventive agents that determines susceptibility to electrophilic xenobiotics. Chem Biol Interact 192: 37–45, 2011.
123.
Hill KE, McCollum GW, Boeglin ME, and Burk RF. Thioredoxin reductase activity is decreased by selenium deficiency. Biochem Biophys Res Commun 234: 293–295, 1997.
124.
Hintze KJ, Wald KA, Zeng H, Jeffery EH, and Finley JW. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. J Nutr 133: 2721–2727, 2003.
125.
Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94: 3633–3638, 1997.
126.
Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274: 27891–27897, 1999.
127.
Holmgren A. Thioredoxin. Annu Rev Biochem 54: 237–271, 1985.
128.
Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2: 811–820, 2000.
129.
Hondal RJ. Using chemical approaches to study selenoproteins-focus on thioredoxin reductases. Biochim Biophys Acta 1790: 1501–1512, 2009.
130.
Hondal RJ and Ruggles EL. Differing views of the role of selenium in thioredoxin reductase. Amino Acids 41: 73–89, 2011.
131.
Hosoya T, Maruyama A, Kang MI, Kawatani Y, Shibata T, Uchida K, Warabi E, Noguchi N, Itoh K, and Yamamoto M. Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J Biol Chem 280: 27244–27250, 2005.
132.
Houghton CA, Fassett RG, and Coombes JS. Sulforaphane: translational research from laboratory bench to clinic. Nutr Rev 71: 709–726, 2013.
133.
Hseu YC, Chou CW, Senthil Kumar KJ, Fu KT, Wang HM, Hsu LS, Kuo YH, Wu CR, Chen SC, and Yang HL. Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes. Food Chem Toxicol 50: 1245–1255, 2012.
134.
Hu C, Eggler AL, Mesecar AD, and van Breemen RB. Modification of keap1 cysteine residues by sulforaphane. Chem Res Toxicol 24: 515–521, 2011.
135.
Hu J, Ma X, Lindner DJ, Karra S, Hofmann ER, Reddy SP, and Kalvakolanu DV. Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the Interferon-Retinoid combination. Oncogene 20: 4235–4248, 2001.
136.
Hu Y, Urig S, Koncarevic S, Wu X, Fischer M, Rahlfs S, Mersch-Sundermann V, and Becker K. Glutathione- and thioredoxin-related enzymes are modulated by sulfur-containing chemopreventive agents. Biol Chem 388: 1069–1081, 2007.
137.
Huang CS, Lin AH, Liu CT, Tsai CW, Chang IS, Chen HW, and Lii CK. Isothiocyanates protect against oxidized LDL-induced endothelial dysfunction by upregulating Nrf2-dependent antioxidation and suppressing NFkappaB activation. Mol Nutr Food Res 57: 1918–1930, 2013.
138.
Huang CS, Lin AH, Yang TC, Liu KL, Chen HW, and Lii CK. Shikonin inhibits oxidized LDL-induced monocyte adhesion by suppressing NFkappaB activation via up-regulation of PI3K/Akt/Nrf2-dependent antioxidation in EA.hy926 endothelial cells. Biochem Pharmacol 93: 352–361, 2015.
139.
Huber RE and Criddle RS. Comparison of the chemical properties of selenocysteine and selenocystine with their sulfur analogs. Arch Biochem Biophys 122: 164–173, 1967.
140.
Hunt PR, Son TG, Wilson MA, Yu QS, Wood WH, Zhang Y, Becker KG, Greig NH, Mattson MP, Camandola S, and Wolkow CA. Extension of lifespan in C. elegans by naphthoquinones that act through stress hormesis mechanisms. PLoS One 6: e21922, 2011.
141.
Immenschuh S and Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7: 768–777, 2005.
142.
Isakov E, Weisman-Shomer P, and Benhar M. Suppression of the pro-inflammatory NLRP3/interleukin-1beta pathway in macrophages by the thioredoxin reductase inhibitor auranofin. Biochim Biophys Acta 1840: 3153–3161, 2014.
143.
Ishii T, Itoh K, Ruiz E, Leake DS, Unoki H, Yamamoto M, and Mann GE. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ Res 94: 609–616, 2004.
144.
Ishii T and Yanagawa T. Stress-induced peroxiredoxins. Subcell Biochem 44: 375–384, 2007.
145.
Ishikado A, Nishio Y, Morino K, Ugi S, Kondo H, Makino T, Kashiwagi A, and Maegawa H. Low concentration of 4-hydroxy hexenal increases heme oxygenase-1 expression through activation of Nrf2 and antioxidative activity in vascular endothelial cells. Biochem Biophys Res Commun 402: 99–104, 2010.
146.
Itoh K, Igarashi K, Hayashi N, Nishizawa M, and Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol Cell Biol 15: 4184–4193, 1995.
147.
Itoh K, Mimura J, and Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 13: 1665–1678, 2010.
148.
Itoh K, Mochizuki M, Ishii Y, Ishii T, Shibata T, Kawamoto Y, Kelly V, Sekizawa K, Uchida K, and Yamamoto M. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol Cell Biol 24: 36–45, 2004.
149.
Iverson SV, Eriksson S, Xu J, Prigge JR, Talago EA, Meade TA, Meade ES, Capecchi MR, Arner ES, and Schmidt EE. A Txnrd1-dependent metabolic switch alters hepatic lipogenesis, glycogen storage, and detoxification. Free Radic Biol Med 63: 369–380, 2013.
150.
Jain AK and Jaiswal AK. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J Biol Chem 281: 12132–12142, 2006.
151.
Jakubikova J, Sedlak J, Bod'o J, and Bao Y. Effect of isothiocyanates on nuclear accumulation of NF-kappaB, Nrf2, and thioredoxin in caco-2 cells. J Agric Food Chem 54: 1656–1662, 2006.
152.
Jan YH, Heck DE, Dragomir AC, Gardner CR, Laskin DL, and Laskin JD. Acetaminophen reactive intermediates target hepatic thioredoxin reductase. Chem Res Toxicol 27: 882–894, 2014.
153.
Jan YH, Heck DE, Gray JP, Zheng H, Casillas RP, Laskin DL, and Laskin JD. Selective targeting of selenocysteine in thioredoxin reductase by the half mustard 2-chloroethyl ethyl sulfide in lung epithelial cells. Chem Res Toxicol 23: 1045–1053, 2010.
154.
Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, Mick R, Tuttle SW, and Koumenis C. Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res 70: 1941–1950, 2010.
155.
Jeong WS, Keum YS, Chen C, Jain MR, Shen G, Kim JH, Li W, and Kong AN. Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells. J Biochem Mol Biol 38: 167–176, 2005.
156.
Jiang J, Mo ZC, Yin K, Zhao GJ, Lv YC, Ouyang XP, Jiang ZS, Fu Y, and Tang CK. Epigallocatechin-3-gallate prevents TNF-alpha-induced NF-kappaB activation thereby upregulating ABCA1 via the Nrf2/Keap1 pathway in macrophage foam cells. Int J Mol Med 29: 946–956, 2012.
157.
Johansson L, Chen C, Thorell JO, Fredriksson A, Stone-Elander S, Gafvelin G, and Arner ES. Exploiting the 21st amino acid-purifying and labeling proteins by selenolate targeting. Nat Methods 1: 61–66, 2004.
158.
Jung CL, Kim HJ, Park JH, Kong AN, Lee CH, and Kim JS. Synergistic activation of the Nrf2-signaling pathway by glyceollins under oxidative stress induced by glutathione depletion. J Agric Food Chem 61: 4072–4078, 2013.
159.
Kanzok SM, Fechner A, Bauer H, Ulschmid JK, Muller HM, Botella-Munoz J, Schneuwly S, Schirmer R, and Becker K. Substitution of the thioredoxin system for glutathione reductase in Drosophila melanogaster. Science 291: 643–646, 2001.
160.
Kataoka K, Handa H, and Nishizawa M. Induction of cellular antioxidative stress genes through heterodimeric transcription factor Nrf2/small Maf by antirheumatic gold(I) compounds. J Biol Chem 276: 34074–34081, 2001.
161.
Kim H, Kim W, Yum S, Hong S, Oh JE, Lee JW, Kwak MK, Park EJ, Na DH, and Jung Y. Caffeic acid phenethyl ester activation of Nrf2 pathway is enhanced under oxidative state: structural analysis and potential as a pathologically targeted therapeutic agent in treatment of colonic inflammation. Free Radic Biol Med 65: 552–562, 2013.
162.
Kim HY. The methionine sulfoxide reduction system: selenium utilization and methionine sulfoxide reductase enzymes and their functions. Antioxid Redox Signal 19: 958–969, 2013.
163.
Kim JK and Jang HD. Nrf2-mediated HO-1 induction coupled with the ERK signaling pathway contributes to indirect antioxidant capacity of caffeic acid phenethyl ester in HepG2 cells. Int J Mol Sci 15: 12149–12165, 2014.
164.
Kim NH, Oh MK, Park HJ, and Kim IS. Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation. J Pharmacol Sci 113: 246–254, 2010.
165.
Kim YS, Zerin T, and Song HY. Antioxidant action of ellagic acid ameliorates paraquat-induced A549 cytotoxicity. Biol Pharm Bull 36: 609–615, 2013.
166.
Kimura A, Ishida Y, Hayashi T, Wada T, Yokoyama H, Sugaya T, Mukaida N, and Kondo T. Interferon-gamma plays protective roles in sodium arsenite-induced renal injury by up-regulating intrarenal multidrug resistance-associated protein 1 expression. Am J Pathol 169: 1118–1128, 2006.
167.
Kitaoka Y, Ogborn DI, Nilsson MI, Mocellin NJ, MacNeil LG, and Tarnopolsky MA. Oxidative stress and Nrf2 signaling in McArdle disease. Mol Genet Metab 110: 297–302, 2013.
168.
Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, and Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130–7139, 2004.
169.
Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Kaneko H, Nakayama Y, Eguchi M, Wada Y, Kumagai Y, and Yamamoto M. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 29: 493–502, 2009.
170.
Kotyzova D, Bludovska M, and Eybl V. Differential influences of various arsenic compounds on antioxidant defense system in liver and kidney of rats. Environ Toxicol Pharmacol 36: 1015–1021, 2013.
171.
Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, and Williams DL. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 4: e206, 2007.
172.
Laborde E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 17: 1373–1380, 2010.
173.
Landar A, Zmijewski JW, Dickinson DA, Le Goffe C, Johnson MS, Milne GL, Zanoni G, Vidari G, Morrow JD, and Darley-Usmar VM. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Am J Physiol Heart Circ Physiol 290: H1777– H1787, 2006.
174.
Lecane PS, Karaman MW, Sirisawad M, Naumovski L, Miller RA, Hacia JG, and Magda D. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 65: 11676–11688, 2005.
175.
Lee BC, Dikiy A, Kim HY, and Gladyshev VN. Functions and evolution of selenoprotein methionine sulfoxide reductases. Biochim Biophys Acta 1790: 1471–1477, 2009.
176.
Lee HR, Cho JM, Shin DH, Yong CS, Choi HG, Wakabayashi N, and Kwak MK. Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine: involvement of Nrf2 activation. Mol Cell Biochem 318: 23–31, 2008.
177.
Lee SB, Cha KH, Selenge D, Solongo A, and Nho CW. The chemopreventive effect of taxifolin is exerted through ARE-dependent gene regulation. Biol Pharm Bull 30: 1074–1079, 2007.
178.
Lee SR, Bar-Noy S, Kwon J, Levine RL, Stadtman TC, and Rhee SG. Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc Natl Acad Sci USA 97: 2521–2526, 2000.
179.
Lee Y, Shin DH, Kim JH, Hong S, Choi D, Kim YJ, Kwak MK, and Jung Y. Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. Eur J Pharmacol 643: 21–28, 2010.
180.
Leonardo CC, Agrawal M, Singh N, Moore JR, Biswal S, and Dore S. Oral administration of the flavanol (-)-epicatechin bolsters endogenous protection against focal ischemia through the Nrf2 cytoprotective pathway. Eur J Neurosci 38: 3659–3668, 2013.
181.
Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, and Darley-Usmar VM. Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 21: 1846–1851, 2001.
182.
Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, Morrow JD, and Darley-Usmar VM. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 378: 373–382, 2004.
183.
Li H, Wu S, Chen J, Wang B, and Shi N. Effect of glutathione depletion on Nrf2/ARE activation by deltamethrin in PC12 Cells. Arh Hig Rada Toksikol 64: 87–97, 2013.
184.
Li W and Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 48: 91–104, 2009.
185.
Li W, Yu SW, and Kong AN. Nrf2 possesses a redox-sensitive nuclear exporting signal in the Neh5 transactivation domain. J Biol Chem 281: 27251–27263, 2006.
186.
Liao BC, Hsieh CW, Liu YC, Tzeng TT, Sun YW, and Wung BS. Cinnamaldehyde inhibits the tumor necrosis factor-alpha-induced expression of cell adhesion molecules in endothelial cells by suppressing NF-kappaB activation: effects upon IkappaB and Nrf2. Toxicol Appl Pharmacol 229: 161–171, 2008.
187.
Lillig CH, Berndt C, and Holmgren A. Glutaredoxin systems. Biochim Biophys Acta 1780: 1304–1317, 2008.
188.
Lillig CH and Holmgren A. Thioredoxin and related molecules—from biology to health and disease. Antioxid Redox Signal 9: 25–47, 2007.
189.
Lin S, Cullen WR, and Thomas DJ. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol 12: 924–930, 1999.
190.
Lin S, Del Razo LM, Styblo M, Wang C, Cullen WR, and Thomas DJ. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 14: 305–311, 2001.
191.
Liu Q, Zhang H, Smeester L, Zou F, Kesic M, Jaspers I, Pi J, and Fry RC. The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 3: 37, 2010.
192.
Locy ML, Rogers LK, Prigge JR, Schmidt EE, Arner ES, and Tipple TE. Thioredoxin reductase inhibition elicits Nrf2-mediated responses in Clara cells: implications for oxidant-induced lung injury. Antioxid Redox Signal 17: 1407–1416, 2012.
193.
Lopez-Otin C and Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 10: 278–292, 2010.
194.
Lothrop AP, Ruggles EL, and Hondal RJ. No selenium required: reactions catalyzed by mammalian thioredoxin reductase that are independent of a selenocysteine residue. Biochemistry 48: 6213–6223, 2009.
195.
Lothrop AP, Snider GW, Ruggles EL, and Hondal RJ. Why is mammalian thioredoxin reductase 1 so dependent upon the use of selenium? Biochemistry 53: 554–565, 2014.
196.
Lu J, Chew EH, and Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 104: 12288–12293, 2007.
197.
Lu J and Holmgren A. Thioredoxin system in cell death progression. Antioxid Redox Signal 17: 1738–1747, 2012.
198.
Lu J and Holmgren A. The thioredoxin antioxidant system. Free Radic Biol Med 66: 75–87, 2014.
199.
Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, and Holmgren A. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66: 4410–4418, 2006.
200.
Luis A, Martins JD, Silva A, Ferreira I, Cruz MT, and Neves BM. Oxidative stress-dependent activation of the eIF2alpha-ATF4 UPR branch by skin sensitizer DNFB modulates dendritic-like cell maturation and inflammatory status in a biphasic manner. Free Radic Biol Med 77: 217–229, 2014.
201.
Luthman M and Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry 21: 6628–6633, 1982.
202.
Ma X, Karra S, Guo W, Lindner DJ, Hu J, Angell JE, Hofmann ER, Reddy SP, and Kalvakolanu DV. Regulation of interferon and retinoic acid-induced cell death activation through thioredoxin reductase. J Biol Chem 276: 24843–24854, 2001.
203.
Ma X, Karra S, Lindner DJ, Hu J, Reddy SP, Kimchi A, Yodoi J, and Kalvakolanu DV. Thioredoxin participates in a cell death pathway induced by interferon and retinoid combination. Oncogene 20: 3703–3715, 2001.
204.
Magesh S, Chen Y, and Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev 32: 687–726, 2012.
205.
Mahmood DF, Abderrazak A, El Hadri K, Simmet T, and Rouis M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal 19: 1266–1303, 2013.
206.
Makabe S, Takahashi Y, Watanabe H, Murakami M, Ohba T, and Ito H. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis 213: 377–384, 2010.
207.
Mandal PK, Schneider M, Kolle P, Kuhlencordt P, Forster H, Beck H, Bornkamm GW, and Conrad M. Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res 70: 9505–9514, 2010.
208.
Marinho HS, Real C, Cyrne L, Soares H, and Antunes F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biol 2: 535–562, 2014.
209.
Massrieh W, Derjuga A, and Blank V. Induction of endogenous Nrf2/small maf heterodimers by arsenic-mediated stress in placental choriocarcinoma cells. Antioxid Redox Signal 8: 53–59, 2006.
210.
Masutani H, Otsuki R, Yamaguchi Y, Takenaka M, Kanoh N, Takatera K, Kunimoto Y, and Yodoi J. Fragrant unsaturated aldehydes elicit activation of the Keap1/Nrf2 system leading to the upregulation of thioredoxin expression and protection against oxidative stress. Antioxid Redox Signal 11: 949–962, 2009.
211.
Matsuzawa A and Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 1780: 1325–1336, 2008.
212.
McNally SJ, Harrison EM, Ross JA, Garden OJ, and Wigmore SJ. Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int J Mol Med 19: 165–172, 2007.
213.
Megherbi R, Kiorpelidou E, Foster B, Rowe C, Naisbitt DJ, Goldring CE, and Park BK. Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1. Toxicol Appl Pharmacol 238: 120–132, 2009.
214.
Meister A. On the antioxidant effects of ascorbic acid and glutathione. [Review]. Biochem Pharmacol 44: 1905–1915, 1992.
215.
Meister A and Anderson ME. Glutathione. [Review]. Ann Rev Biochem 52: 711–760, 1983.
216.
Meno SR, Nelson R, Hintze KJ, and Self WT. Exposure to monomethylarsonous acid (MMA(III)) leads to altered selenoprotein synthesis in a primary human lung cell model. Toxicol Appl Pharmacol 239: 130–136, 2009.
217.
Meuillet EJ, Mahadevan D, Berggren M, Coon A, and Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 429: 123–133, 2004.
218.
Misra JR, Horner MA, Lam G, and Thummel CS. Transcriptional regulation of xenobiotic detoxification in Drosophila. Genes Dev 25: 1796–1806, 2011.
219.
Moos PJ, Edes K, Cassidy P, Massuda E, and Fitzpatrick FA. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 278: 745–750, 2003.
220.
Morales AA, Gutman D, Cejas PJ, Lee KP, and Boise LH. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem 284: 12886–12895, 2009.
221.
Mostert V, Hill KE, and Burk RF. Loss of activity of the selenoenzyme thioredoxin reductase causes induction of hepatic heme oxygenase-1. FEBS Lett 541: 85–88, 2003.
222.
Mostert V, Hill KE, Ferris CD, and Burk RF. Selective induction of liver parenchymal cell heme oxygenase-1 in selenium-deficient rats. Biol Chem 384: 681–687, 2003.
223.
Motterlini R, Foresti R, Bassi R, and Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 28: 1303–1312, 2000.
224.
Muller M, Banning A, Brigelius-Flohe R, and Kipp A. Nrf2 target genes are induced under marginal selenium-deficiency. Genes Nutr 5: 297–307, 2010.
225.
Na HK and Surh YJ. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem Toxicol 46: 1271–1278, 2008.
226.
Nakamura Y and Miyoshi N. Electrophiles in foods: the current status of isothiocyanates and their chemical biology. Biosci Biotechnol Biochem 74: 242–255, 2010.
227.
Nauser T, Dockheer S, Kissner R, and Koppenol WH. Catalysis of electron transfer by selenocysteine. Biochemistry 45: 6038–6043, 2006.
228.
Nauser T, Steinmann D, and Koppenol WH. Why do proteins use selenocysteine instead of cysteine? Amino Acids 42: 39–44, 2012.
229.
Nguyen T, Sherratt PJ, Huang HC, Yang CS, and Pickett CB. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem 278: 4536–4541, 2003.
230.
Nikaido M, Pi J, Kumagai Y, Yamauchi H, Taguchi K, Horiguchi S, Sun Y, Sun G, and Shimojo N. Decreased enzyme activity of hepatic thioredoxin reductase and glutathione reductase in rabbits by prolonged exposure to inorganic arsenate. Environ Toxicol 18: 306–311, 2003.
231.
Niture SK, Jain AK, and Jaiswal AK. Antioxidant-induced modification of INrf2 cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J Cell Sci 122: 4452–4464, 2009.
232.
Nordberg J and Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 31: 1287–1312, 2001.
233.
Nordberg J, Zhong L, Holmgren A, and Arner ES. Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J Biol Chem 273: 10835–10842, 1998.
234.
Novoselov SV and Gladyshev VN. Non-animal origin of animal thioredoxin reductases: implications for selenocysteine evolution and evolution of protein function through carboxy-terminal extensions. Protein Sci 12: 372–378, 2003.
235.
Oh JY, Giles N, Landar A, and Darley-Usmar V. Accumulation of 15-deoxy-delta(12,14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defence induction. Biochem J 411: 297–306, 2008.
236.
Okazaki S, Naganuma A, and Kuge S. Peroxiredoxin-mediated redox regulation of the nuclear localization of Yap1, a transcription factor in budding yeast. Antioxid Redox Signal 7: 327–334, 2005.
237.
Olsson U, Lundgren B, Segura-Aguilar J, Messing-Eriksson A, Andersson K, Becedas L, and De Pierre JW. Effects of selenium deficiency on xenobiotic-metabolizing and other enzymes in rat liver. Int J Vitam Nutr Res 63: 31–37, 1993.
238.
Omata Y, Folan M, Shaw M, Messer RL, Lockwood PE, Hobbs D, Bouillaguet S, Sano H, Lewis JB, and Wataha JC. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1). Toxicol In Vitro 20: 882–890, 2006.
239.
Papp D, Lenti K, Modos D, Fazekas D, Dul Z, Turei D, Foldvari-Nagy L, Nussinov R, Csermely P, and Korcsmaros T. The NRF2-related interactome and regulome contain multifunctional proteins and fine-tuned autoregulatory loops. FEBS Lett 586: 1795–1802, 2012.
240.
Papp LV, Lu J, Holmgren A, and Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9: 775–806, 2007.
241.
Park YS, Misonou Y, Fujiwara N, Takahashi M, Miyamoto Y, Koh YH, Suzuki K, and Taniguchi N. Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. Biochem Biophys Res Commun 327: 1058–1065, 2005.
242.
Patterson AD, Carlson BA, Li F, Bonzo JA, Yoo MH, Krausz KW, Conrad M, Chen C, Gonzalez FJ, and Hatfield DL. Disruption of thioredoxin reductase 1 protects mice from acute acetaminophen-induced hepatotoxicity through enhanced NRF2 activity. Chem Res Toxicol 26: 1088–1096, 2013.
243.
Pekkari K and Holmgren A. Truncated thioredoxin: physiological functions and mechanism. Antioxid Redox Signal 6: 53–61, 2004.
244.
Peng X, Mandal PK, Kaminskyy VO, Lindqvist A, Conrad M, and Arner ES. Sec-containing TrxR1 is essential for self-sufficiency of cells by control of glucose-derived H2O2. Cell Death Dis 5: e1235, 2014.
245.
Peng X, Xu J, and Arner ES. Thiophosphate and selenite conversely modulate cell death induced by glutathione depletion or cisplatin: effects related to activity and Sec contents of thioredoxin reductase. Biochem J 447: 167–174, 2012.
246.
Pompella A, Visvikis A, Paolicchi A, De Tata V, and Casini AF. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 66: 1499–1503, 2003.
247.
Poole LB, Hall A, and Nelson KJ. Overview of peroxiredoxins in oxidant defense and redox regulation. Curr Protoc Toxicol Chapter 7: Unit7.9, 2011.
248.
Prast-Nielsen S, Cebula M, Pader I, and Arner ES. Noble metal targeting of thioredoxin reductase—covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin. Free Radic Biol Med 49: 1765–1778, 2010.
249.
Prigge JR, Eriksson S, Iverson SV, Meade TA, Capecchi MR, Arner ES, and Schmidt EE. Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1. Free Radic Biol Med 52: 803–810, 2012.
250.
Przybysz AJ, Choe KP, Roberts LJ, and Strange K. Increased age reduces DAF-16 and SKN-1 signaling and the hormetic response of Caenorhabditis elegans to the xenobiotic juglone. Mech Ageing Dev 130: 357–369, 2009.
251.
Qin S, Chen J, Tanigawa S, and Hou DX. Microarray and pathway analysis highlight Nrf2/ARE-mediated expression profiling by polyphenolic myricetin. Mol Nutr Food Res 57: 435–446, 2013.
252.
Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, and Freeman ML. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem Res Toxicol 21: 705–710, 2008.
253.
Randall MJ, Spiess PC, Hristova M, Hondal RJ, and van der Vliet A. Acrolein-induced activation of mitogen-activated protein kinase signaling is mediated by alkylation of thioredoxin reductase and thioredoxin 1. Redox Biol 1: 265–275, 2013.
254.
Rhee SG, Chae HZ, and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543–1552, 2005.
255.
Rhee SG, Kang SW, Chang TS, Jeong W, and Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52: 35–41, 2001.
256.
Rhee SG and Woo HA. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H(2)O(2), and protein chaperones. Antioxid Redox Signal 15: 781–794, 2011.
257.
Rhee SG, Woo HA, Kil IS, and Bae SH. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J Biol Chem 287: 4403–4410, 2012.
258.
Riedl MA, Saxon A, and Diaz-Sanchez D. Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway. Clin Immunol 130: 244–251, 2009.
259.
Rigobello MP, Folda A, Baldoin MC, Scutari G, and Bindoli A. Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic Res 39: 687–695, 2005.
260.
Rigobello MP, Folda A, Dani B, Menabo R, Scutari G, and Bindoli A. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur J Pharmacol 582: 26–34, 2008.
261.
Rundlof AK, Janard M, Miranda-Vizuete A, and Arner ES. Evidence for intriguingly complex transcription of human thioredoxin reductase 1. Free Radic Biol Med 36: 641–656, 2004.
262.
Saccoccia F, Angelucci F, Boumis G, Carotti D, Desiato G, Miele AE, and Bellelli A. Thioredoxin reductase and its inhibitors. Curr Protein Pept Sci 15: 621–646, 2014.
263.
Sahin K, Tuzcu M, Gencoglu H, Dogukan A, Timurkan M, Sahin N, Aslan A, and Kucuk O. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sci 87: 240–245, 2010.
264.
Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596–2606, 1998.
265.
Sakurai A, Yuasa K, Shoji Y, Himeno S, Tsujimoto M, Kunimoto M, Imura N, and Hara S. Overexpression of thioredoxin reductase 1 regulates NF-kappa B activation. J Cell Physiol 198: 22–30, 2004.
266.
Sandalova T, Zhong L, Lindqvist Y, Holmgren A, and Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci USA 98: 9533–9538, 2001.
267.
Saw CL, Guo Y, Yang AY, Paredes-Gonzalez X, Ramirez C, Pung D, and Kong AN. The berry constituents quercetin, kaempferol, and pterostilbene synergistically attenuate reactive oxygen species: involvement of the Nrf2-ARE signaling pathway. Food Chem Toxicol 72: 303–311, 2014.
268.
Scapagnini G, Colombrita C, Amadio M, D'Agata V, Arcelli E, Sapienza M, Quattrone A, and Calabrese V. Curcumin activates defensive genes and protects neurons against oxidative stress. Antioxid Redox Signal 8: 395–403, 2006.
269.
Sengupta A, Carlson BA, Weaver JA, Novoselov SV, Fomenko DE, Gladyshev VN, and Hatfield DL. A functional link between housekeeping selenoproteins and phase II enzymes. Biochem J 413: 151–161, 2008.
270.
Sengupta R and Holmgren A. Thioredoxin and thioredoxin reductase in relation to reversible S-nitrosylation. Antioxid Redox Signal 18: 259–269, 2013.
271.
Shah ZA, Li RC, Ahmad AS, Kensler TW, Yamamoto M, Biswal S, and Dore S. The flavanol (-)-epicatechin prevents stroke damage through the Nrf2/HO1 pathway. J Cereb Blood Flow Metab 30: 1951–1961, 2010.
272.
Shelton MD, Chock PB, and Mieyal JJ. Glutaredoxin: role in reversible protein s-glutathionylation and regulation of redox signal transduction and protein translocation. Antioxid Redox Signal 7: 348–366, 2005.
273.
Simmons SO, Fan CY, Yeoman K, Wakefield J, and Ramabhadran R. NRF2 Oxidative stress induced by heavy metals is cell type dependent. Curr Chem Genomics 5: 1–12, 2011.
274.
Smith AD, Guidry CA, Morris VC, and Levander OA. Aurothioglucose inhibits murine thioredoxin reductase activity in vivo. J Nutr 129: 194–198, 1999.
275.
Snider GW, Ruggles E, Khan N, and Hondal RJ. Selenocysteine confers resistance to inactivation by oxidation in thioredoxin reductase: comparison of selenium and sulfur enzymes. Biochemistry 52: 5472–5481, 2013.
276.
Sobotta MC, Liou W, Stocker S, Talwar D, Oehler M, Ruppert T, Scharf AN, and Dick TP. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat Chem Biol 11: 64–70, 2015.
277.
Son TG, Kawamoto EM, Yu QS, Greig NH, Mattson MP, and Camandola S. Naphthazarin protects against glutamate-induced neuronal death via activation of the Nrf2/ARE pathway. Biochem Biophys Res Commun 433: 602–606, 2013.
278.
Sturm N, Hu Y, Zimmermann H, Fritz-Wolf K, Wittlin S, Rahlfs S, and Becker K. Compounds structurally related to ellagic acid show improved antiplasmodial activity. Antimicrob Agents Chemother 53: 622–630, 2009.
279.
Su D and Gladyshev VN. Alternative splicing involving the thioredoxin reductase module in mammals: a glutaredoxin-containing thioredoxin reductase 1. Biochemistry 43: 12177–12188, 2004.
280.
Sun QA, Zappacosta F, Factor VM, Wirth PJ, Hatfield DL, and Gladyshev VN. Heterogeneity within animal thioredoxin reductases. Evidence for alternative first exon splicing. J Biol Chem 276: 3106–3114, 2001.
281.
Sun Y, Huang L, Mackenzie GG, and Rigas B. Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 338: 775–783, 2011.
282.
Surh YJ, Kundu JK, and Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 74: 1526–1539, 2008.
283.
Susan M and Rao MN. Induction of glutathione S-transferase activity by curcumin in mice. Arzneimittelforschung 42: 962–964, 1992.
284.
Suvorova ES, Lucas O, Weisend CM, Rollins MF, Merrill GF, Capecchi MR, and Schmidt EE. Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS One 4: e6158, 2009.
285.
Suzuki T, Kelly VP, Motohashi H, Nakajima O, Takahashi S, Nishimura S, and Yamamoto M. Deletion of the selenocysteine tRNA gene in macrophages and liver results in compensatory gene induction of cytoprotective enzymes by Nrf2. J Biol Chem 283: 2021–2030, 2008.
286.
Sykiotis GP and Bohmann D. Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in Drosophila. Dev Cell 14: 76–85, 2008.
287.
Taguchi K, Motohashi H, and Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16: 123–140, 2011.
288.
Tao L, Forester SC, and Lambert JD. The role of the mitochondrial oxidative stress in the cytotoxic effects of the green tea catechin, (-)-epigallocatechin-3-gallate, in oral cells. Mol Nutr Food Res 58: 665–676, 2014.
289.
Tavender TJ, Springate JJ, and Bulleid NJ. Recycling of peroxiredoxin IV provides a novel pathway for disulphide formation in the endoplasmic reticulum. EMBO J 29: 4185–4197, 2010.
290.
Tchaparian E, Marshal L, Cutler G, Bauerly K, Chowanadisai W, Satre M, Harris C, and Rucker RB. Identification of transcriptional networks responding to pyrroloquinoline quinone dietary supplementation and their influence on thioredoxin expression, and the JAK/STAT and MAPK pathways. Biochem J 429: 515–526, 2010.
291.
Thieme R, Pai EF, Schirmer RH, and Schulz GE. Three-dimensional structure of glutathione reductase at 2 A resolution. J Mol Biol 152: 763–782, 1981.
292.
Tonissen KF and Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 53: 87–103, 2009.
293.
Toppo S, Flohe L, Ursini F, Vanin S, and Maiorino M. Catalytic mechanisms and specificities of glutathione peroxidases: variations of a basic scheme. Biochim Biophys Acta 1790: 1486–1500, 2009.
294.
Trigona WL, Mullarky IK, Cao Y, and Sordillo LM. Thioredoxin reductase regulates the induction of haem oxygenase-1 expression in aortic endothelial cells. Biochem J 394: 207–216, 2006.
295.
Turanov AA, Su D, and Gladyshev VN. Characterization of alternative cytosolic forms and cellular targets of mouse mitochondrial thioredoxin reductase. J Biol Chem 281: 22953–22963, 2006.
296.
Turei D, Papp D, Fazekas D, Foldvari-Nagy L, Modos D, Lenti K, Csermely P, and Korcsmaros T. NRF2-ome: an integrated web resource to discover protein interaction and regulatory networks of NRF2. Oxid Med Cell Longev 2013: 737591, 2013.
297.
Uehara T, Yamate J, Torii M, and Maruyama T. Comparative nephrotoxicity of Cisplatin and nedaplatin: mechanisms and histopathological characteristics. J Toxicol Pathol 24: 87–94, 2011.
298.
Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, and Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809–35815, 1999.
299.
Uruno A and Motohashi H. The Keap1-Nrf2 system as an in vivo sensor for electrophiles. Nitric Oxide 25: 153–160, 2011.
300.
Varma SD, Chandrasekaran K, and Kovtun S. Sulforaphane-induced transcription of thioredoxin reductase in lens: possible significance against cataract formation. Clin Ophthalmol 7: 2091–2098, 2013.
301.
Velichkova M and Hasson T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol Cell Biol 25: 4501–4513, 2005.
302.
Vrba J, Gazak R, Kuzma M, Papouskova B, Vacek J, Weiszenstein M, Kren V, and Ulrichova J. A novel semisynthetic flavonoid 7-O-galloyltaxifolin upregulates heme oxygenase-1 in RAW264.7 cells via MAPK/Nrf2 pathway. J Med Chem 56: 856–866, 2013.
303.
Wang L, Kou MC, Weng CY, Hu LW, Wang YJ, and Wu MJ. Arsenic modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth factor expression in endothelial cells: roles of ROS, NF-kappaB, and MAPK pathways. Arch Toxicol 86: 879–896, 2012.
304.
Wang W, Wang S, Howie AF, Beckett GJ, Mithen R, and Bao Y. Sulforaphane, erucin, and iberin up-regulate thioredoxin reductase 1 expression in human MCF-7 cells. J Agric Food Chem 53: 1417–1421, 2005.
305.
Wang XJ, Hayes JD, and Wolf CR. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res 66: 10983–10994, 2006.
306.
Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu J, and Tang X. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radic Biol Med 70: 68–77, 2014.
307.
Wang Y, Lu H, Wang D, Li S, Sun K, Wan X, Taylor EW, and Zhang J. Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase. Toxicol Appl Pharmacol 265: 342–350, 2012.
308.
Wang Y, Zhang H, Holmgren A, Tian W, and Zhong L. Inhibitory effect of green tea extract and (-)-epigallocatechin-3-gallate on mammalian thioredoxin reductase and HeLa cell viability. Oncol Rep 20: 1479–1487, 2008.
309.
Wataha JC, Lewis JB, McCloud VV, Shaw M, Omata Y, Lockwood PE, Messer RL, and Hansen JM. Effect of mercury(II) on Nrf2, thioredoxin reductase-1 and thioredoxin-1 in human monocytes. Dent Mater 24: 765–772, 2008.
310.
Watson WH, Heilman JM, Hughes LL, and Spielberger JC. Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem Biophys Res Commun 368: 832–836, 2008.
311.
Watson WH, Pohl J, Montfort WR, Stuchlik O, Reed MS, Powis G, and Jones DP. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem 278: 33408–33415, 2003.
312.
Wessjohann LA, Schneider A, Abbas M, and Brandt W. Selenium in chemistry and biochemistry in comparison to sulfur. Biol Chem 388: 997–1006, 2007.
313.
Williams CH, Arscott LD, Muller S, Lennon BW, Ludwig ML, Wang PF, Veine DM, Becker K, and Schirmer RH. Thioredoxin reductase two modes of catalysis have evolved. Eur J Biochem 267: 6110–6117, 2000.
314.
Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 4: 278–286, 2008.
315.
Winterbourn CC and Hampton MB. Thiol chemistry and specificity in redox signaling. Free Radic Biol Med 45: 549–561, 2008.
316.
Witte AB, Anestal K, Jerremalm E, Ehrsson H, and Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39: 696–703, 2005.
317.
Wondrak GT, Cabello CM, Villeneuve NF, Zhang S, Ley S, Li Y, Sun Z, and Zhang DD. Cinnamoyl-based Nrf2-activators targeting human skin cell photo-oxidative stress. Free Radic Biol Med 45: 385–395, 2008.
318.
Wondrak GT, Villeneuve NF, Lamore SD, Bause AS, Jiang T, and Zhang DD. The cinnamon-derived dietary factor cinnamic aldehyde activates the Nrf2-dependent antioxidant response in human epithelial colon cells. Molecules 15: 3338–3355, 2010.
319.
World C, Spindel ON, and Berk BC. Thioredoxin-interacting protein mediates TRX1 translocation to the plasma membrane in response to tumor necrosis factor-alpha: a key mechanism for vascular endothelial growth factor receptor-2 transactivation by reactive oxygen species. Arterioscler Thromb Vasc Biol 31: 1890–1897, 2011.
320.
Wu C, Parrott AM, Fu C, Liu T, Marino SM, Gladyshev VN, Jain MR, Baykal AT, Li Q, Oka S, Sadoshima J, Beuve A, Simmons WJ, and Li H. Thioredoxin 1-mediated post-translational modifications: reduction, transnitrosylation, denitrosylation, and related proteomics methodologies. Antioxid Redox Signal 15: 2565–2604, 2011.
321.
Xu J and Arner ES. Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase. Biochem Pharmacol 83: 815–820, 2012.
322.
Xu J, Eriksson S, Cebula M, Sandalova T, Hedstrom E, Pader I, Cheng Q, Myers CR, Antholine WE, Nagy P, Hellman U, Selivanova G, Lindqvist Y, and Arnér ESJ. The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerisation and crosslinking upon oxidative stress related to cell death. Cell Death Dis 6: e1616, 2015.
323.
Xu XH, Hua YN, Zhang HL, Wu JC, Miao YZ, Han R, Gu ZL, and Qin ZH. Greater stress protein expression enhanced by combined prostaglandin A1 and lithium in a rat model of focal ischemia. Acta Pharmacol Sin 28: 1097–1104, 2007.
324.
Yan XD, Kumar B, Nahreini P, Hanson AJ, Prasad JE, and Prasad KN. Prostaglandin-induced neurodegeneration is associated with increased levels of oxidative markers and reduced by a mixture of antioxidants. J Neurosci Res 81: 85–90, 2005.
325.
Yang C, Zhang X, Fan H, and Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res 1282: 133–141, 2009.
326.
Yant LJ, Ran Q, Rao L, Van Remmen H, Shibatani T, Belter JG, Motta L, Richardson A, and Prolla TA. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic Biol Med 34: 496–502, 2003.
327.
Yoshihara E, Chen Z, Matsuo Y, Masutani H, and Yodoi J. Thiol redox transitions by thioredoxin and thioredoxin-binding protein-2 in cell signaling. Methods Enzymol 474: 67–82, 2010.
328.
Yu Z, Shao W, Chiang Y, Foltz W, Zhang Z, Ling W, Fantus IG, and Jin T. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 54: 922–934, 2011.
329.
Zhang DD and Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23: 8137–8151, 2003.
330.
Zhang H, Cao D, Cui W, Ji M, Qian X, and Zhong L. Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate. Free Radic Biol Med 49: 2010–2018, 2010.
331.
Zhang H, Du Y, Zhang X, Lu J, and Holmgren A. Glutaredoxin 2 reduces both thioredoxin 2 and thioredoxin 1 and protects cells from apoptosis induced by auranofin and 4-hydroxynonenal. Antioxid Redox Signal 21: 669–681, 2014.
332.
Zhang J and Lu H. Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity. Free Radic Biol Med 43: 1574–1583, 2007.
333.
Zhang Q, Ding M, Cao Z, Zhang J, Ding F, and Ke K. Pyrroloquinoline quinine protects rat brain cortex against acute glutamate-induced neurotoxicity. Neurochem Res 38: 1661–1671, 2013.
334.
Zhang Q, Ding M, Gao XR, and Ding F. Pyrroloquinoline quinone rescues hippocampal neurons from glutamate-induced cell death through activation of Nrf2 and up-regulation of antioxidant genes. Genet Mol Res 11: 2652–2664, 2012.
335.
Zheng Y, Morris A, Sunkara M, Layne J, Toborek M, and Hennig B. Epigallocatechin-gallate stimulates NF-E2-related factor and heme oxygenase-1 via caveolin-1 displacement. J Nutr Biochem 23: 163–168, 2012.
336.
Zhong L, Arner ES, and Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci U S A 97: 5854–5859, 2000.
337.
Zhong L, Arnér ESJ, Ljung J, Åslund F, and Holmgren A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J Biol Chem 273: 8581–8591, 1998.
338.
Zhong L and Holmgren A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J Biol Chem 275: 18121–18128, 2000.

Information & Authors

Information

Published In

cover image Antioxidants & Redox Signaling
Antioxidants & Redox Signaling
Volume 23Issue Number 10October 1, 2015
Pages: 823 - 853
PubMed: 26058897

History

Published in print: October 1, 2015
Published online: 25 September 2015
Published ahead of print: 24 June 2015
Published ahead of production: 21 May 2015
Accepted: 20 May 2015
Received: 13 May 2015

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Marcus Cebula
Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Edward E. Schmidt
Microbiology and Immunology, Montana State University, Bozeman, Montana.
Elias S.J. Arnér
Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

Notes

Address correspondence to:Prof. Elias S.J. ArnérDivision of BiochemistryDepartment of Medical Biochemistry and BiophysicsKarolinska InstitutetStockholm SE-171 77Sweden
E-mail: [email protected]

Author Contributions

M.C., E.E.S., and E.S.J.A. jointly wrote this article, in parts initially based on the PhD thesis of M.C. titled “Intricate aspects of the thioredoxin system in redox signaling” and defended at Karolinska Institutet on May 23, 2014 (http://hdl.handle.net/10616/41953).

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top